{"drugs":["Kuvan","Sapropterin Dihydrochloride"],"mono":{"0":{"id":"928931-s-0","title":"Generic Names","mono":"Sapropterin Dihydrochloride"},"1":{"id":"928931-s-1","title":"Dosing and Indications","sub":{"0":{"id":"928931-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Phenylketonuria, In patients responsive to tetrahydrobiopterin:<\/b> initial, 10 to 20 mg\/kg ORALLY once daily; if phenylalanine levels do not decrease after 1 month at 10 mg\/kg, increase to 20 mg\/kg\/day; if phenylalanine levels do not decrease after 1 month at 20 mg\/kg\/day, discontinue use<\/li><li><b>Phenylketonuria, In patients responsive to tetrahydrobiopterin:<\/b> maintenance, 5 to 20 mg\/kg ORALLY once daily<\/li><\/ul>"},"1":{"id":"928931-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Phenylketonuria, In patients responsive to tetrahydrobiopterin:<\/b> (1 month to 6 years) initial, 10 mg\/kg ORALLY once daily; if phenylalanine levels do not decrease after 1 month at 10 mg\/kg, increase to 20 mg\/kg\/day; if phenylalanine levels do not decrease after 1 month at 20 mg\/kg\/day, discontinue use<\/li><li><b>Phenylketonuria, In patients responsive to tetrahydrobiopterin:<\/b> (7 years or older) initial, 10 to 20 mg\/kg ORALLY once daily; if phenylalanine levels do not decrease after 1 month at 10 mg\/kg, increase to 20 mg\/kg\/day; if phenylalanine levels do not decrease after 1 month at 20 mg\/kg\/day, discontinue use<\/li><li><b>Phenylketonuria, In patients responsive to tetrahydrobiopterin:<\/b> maintenance, 5 to 20 mg\/kg ORALLY once daily<\/li><\/ul>"},"3":{"id":"928931-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Phenylketonuria, In patients responsive to tetrahydrobiopterin<br\/>"}}},"3":{"id":"928931-s-3","title":"Contraindications\/Warnings","sub":[{"id":"928931-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"928931-s-3-10","title":"Precautions","mono":"<ul><li>Hepatic:<\/li><li>-- monitoring recommended with preexisting hepatic impairment<\/li><li>Gastrointestinal:<\/li><li>-- serious gastritis has been reported; monitoring recommended<\/li><li>Endocrine:<\/li><li>-- risk of hypophenylalaninemia is increased in children younger than 7 years; monitor phenylalanine levels frequently in pediatric patients<\/li><li>-- all patients who receive treatment should also follow a phenylalanine-restricted diet<\/li><li>Immunologic:<\/li><li>-- anaphylaxis and other hypersensitivity reactions have occurred; use not recommended with history of anaphylaxis to sapropterin dihydrochloride; discontinue drug if anaphylaxis develops, but continue dietary phenylalanine restrictions<\/li><li>Neurologic:<\/li><li>-- hyperactivity has been reported; monitoring recommended<\/li><li>Renal:<\/li><li>-- monitoring recommended with preexisting renal impairment<\/li><li>Other:<\/li><li>-- discontinue if lack of clinical response is evident following up to 2 months of therapy (including dose titration)<\/li><li>Concomitant Use:<\/li><li>-- monitoring recommended with concomitant use of drugs known to affect folate metabolism (eg, methotrexate)<\/li><li>-- increased risk of hypotension with concurrent use of drugs that affect nitric oxide-mediated vasorelaxation (eg, sildenafil, tadalafil, vardenafil); monitoring recommended<\/li><li>-- concurrent use with levodopa in patients with preexisting neurologic disorders increased the risk of new or worsening seizures, overstimulation, or irritability; monitoring recommended<\/li><\/ul>"},{"id":"928931-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"928931-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"928931-s-4","title":"Drug Interactions","sub":{"2":{"id":"928931-s-4-15","title":"Moderate","mono":"<ul>Levodopa (probable)<\/ul>"}}},"5":{"id":"928931-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Diarrhea (4% or more), Vomiting (4% or more)<\/li><li><b>Neurologic:<\/b>Headache (4% or greater)<\/li><li><b>Respiratory:<\/b>Cough (4% or more), Nasal congestion (4% or more), Nasal discharge (4% or more), Pain in throat (4% or more), Upper respiratory infection (17%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Myocardial infarction<\/li><li><b>Gastrointestinal:<\/b>Gastrointestinal hemorrhage<\/li><li><b>Hematologic:<\/b>Hemorrhage, Post-procedural<\/li><li><b>Neurologic:<\/b>Seizure<\/li><li><b>Respiratory:<\/b>Respiratory failure<\/li><\/ul>"},"6":{"id":"928931-s-6","title":"Drug Name Info","sub":{"0":{"id":"928931-s-6-17","title":"US Trade Names","mono":"Kuvan<br\/>"},"2":{"id":"928931-s-6-19","title":"Class","mono":"Endocrine-Metabolic Agent<br\/>"},"3":{"id":"928931-s-6-20","title":"Regulatory Status","mono":"RX\/OTC<br\/>"},"4":{"id":"928931-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"928931-s-7","title":"Mechanism Of Action","mono":"Sapropterin dihydrochloride, a biologically active synthetic form of tetrahydrobiopterin (BH4), reduces blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) by activating residual phenylalanine hydroxylase (PAH) enzymes and improving the normal oxidative metabolism of Phe. Phe levels will be reduced in some patients.<br\/>"},"8":{"id":"928931-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"928931-s-8-23","title":"Absorption","mono":"<ul><li>Bioavailability, Oral (intact tablet): 40% greater compared with dissolved tablet administration<\/li><li>Effect of food, Oral (dissolved tablet): increase in AUC by 87% and Cmax by 84%<\/li><li>Effect of food, Oral (intact tablet): systemic absorption increased by 43% compared with dissolved tablet<\/li><\/ul>"},"3":{"id":"928931-s-8-26","title":"Excretion","mono":"Total body clearance: 37.9 to 81.5 L\/hr\/kg <br\/>"},"4":{"id":"928931-s-8-27","title":"Elimination Half Life","mono":"approximately 6.7 hours <br\/>"}}},"9":{"id":"928931-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>take with food, preferably at the same meal daily<\/li><li>(oral tablets) may swallow whole or may dissolve tablets in 4 to 8 oz (120 to 240 mL) of water or apple juice; take within 15 minutes of dissolution; may crush or stir tablets to facilitate dissolution, and small tablet pieces may float on top; or may crush and mix into soft foods such as applesauce or pudding<\/li><li>(powder for oral solution) dissolve in 4 to 8 oz (120 to 240 mL) of water or apple juice; take within 30 minutes of dissolution<\/li><li>(weight 10 kg or less, powder for oral solution) dissolve 1 or 2 packets in 5 or 10 mL of water or apple juice; administer calculated portion using an oral syringe<\/li><li>missed dose should be taken as soon as possible, but 2 doses should not be taken on the same day<\/li><\/ul>"},"10":{"id":"928931-s-10","title":"Monitoring","mono":"<ul><li>phenylalanine blood levels; at baseline, after 1 week of therapy, periodically for 1 month after initiation or dose increase, and routinely throughout treatment; frequent monitoring recommended in pediatric patients and patients treated with agents known to affect folate metabolism<\/li><li>liver function tests; in patients with hepatic impairment during therapy<\/li><li>signs and symptoms of gastritis during therapy<\/li><li>blood pressure during therapy in patients treated with agents know to affect nitric oxide-mediated vasorelaxation (eg, sildenafil, vardenafil, tadalafil)<\/li><li>neurological status during therapy in patients with preexisting neurologic disorders treated with levodopa.<\/li><li>signs or symptoms of hyperactivity during therapy<\/li><li>clinical status in patients with renal impairment<\/li><\/ul>"},"11":{"id":"928931-s-11","title":"How Supplied","mono":"<b>Kuvan<\/b><br\/><ul><li>Oral Powder for Solution: 100 MG, 500 MG<\/li><li>Oral Tablet, Disintegrating: 100 MG<\/li><\/ul>"},"13":{"id":"928931-s-13","title":"Clinical Teaching","mono":"<ul><li>Instruct patient to follow a phenylalanine-restricted diet and report any changes to dietary phenylalanine levels while taking this drug.<\/li><li>Side effects may include headache, diarrhea, vomiting, cough, or congestion.<\/li><li>Instruct patient to take drug with food at approximately the same time each day. Oral tablets and powder for solution should be consumed within 15 and 30 minutes of dissolution, respectively.<\/li><li> If a dose is missed the next dose should be taken as soon as possible; however 2 doses should not be administered on the same day.<\/li><\/ul>"}}}